Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
23 Septiembre 2024 - 6:00AM
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology
company developing novel, investigational engineered cytokine
therapies designed to address areas of unmet need for patients with
a variety of cancers, today announced the appointment of Sachiyo
Minegishi to its board of directors, effective September 20. Ms.
Minegishi will serve as Chair of the Audit Committee and will also
be joining the company’s Nominating and Corporate Governance
Committee.
“With over 20 years of industry experience, Sachiyo brings a
successful record of helping companies navigate through important
clinical, financial, and corporate milestones,” said Caroline Loew,
Ph.D., CEO of Mural Oncology. “Her diverse expertise will be
invaluable as we look to propel Mural through the next stage of
growth, with several key milestones including candidate nominations
for our IL-18 and IL-12 programs this year and key readouts in our
two potentially registrational studies of nemvaleukin in the first
half of 2025.”
Sachiyo brings over two decades of biopharma experience, with a
focus on corporate strategy, finance, development, and
commercialization. She is currently the Chief Operating Officer at
Rectify Pharmaceuticals, driving corporate and financing strategy
to advance its lead program from discovery to clinical stage. Prior
to Rectify, Sachiyo was Chief Financial Officer at Akouos, Inc.,
where she led corporate finance and business development strategy
and played a key role in the acquisition of the company by Eli
Lilly. Before that, she was a Global Program Lead at bluebird bio,
where she led a team to execute global development and
commercialization strategy for a portfolio of gene therapies for
sickle cell disease. Sachiyo has also held leadership roles that
helped accelerate corporate growth at Human Genome Sciences,
Genzyme, and Amgen.
“Mural is entering an exciting time of growth, as it leverages
its unique protein engineering skills to develop novel and highly
differentiated immunotherapies for patients with high unmet need,”
said Sachiyo. “I look forward to contributing my corporate and
financing strategy expertise to help position the company for
potential commercialization of its lead program and advancement of
its early-stage pipeline to the clinic.”
About Mural OncologyMural Oncology is
leveraging its novel protein engineering platform to develop
cytokine-based immunotherapies for the treatment of cancer. By
combining our expertise in cytokine biology and immune cell
modulation and our protein engineering platform, we are developing
medicines to deliver meaningful and clinical benefits to people
living with cancer. Our mission is to broaden the potential,
and reach, of cytokine-based immunotherapies to improve the lives
of patients. Our lead candidate, nemvaleukin, is currently in
potentially registrational trials in mucosal melanoma and
platinum-resistant ovarian cancer reading out in the first half of
2025. Mural Oncology has its registered office in Dublin, Ireland,
and its primary facilities in Waltham, Mass. For more information,
visit Mural Oncology’s website at www.muraloncology.com and
follow us on LinkedIn and X.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to, statements regarding: the company’s pipeline and
development programs, including the expected timing of clinical
updates from the ARTISTRY-6 and ARTISTRY-7 trials, the expected
timing of preclinical updates and candidate selection, including
with respect to the company’s IL-12 and IL-18 programs, the
potential of the company’s product candidates and programs to
address unmet medical needs, and the continued progress of its
pipeline and programs. Any forward-looking statements in this press
release are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
Risks that contribute to the uncertain nature of the
forward-looking statements include, among others, the inherent
risks and uncertainties associated with competitive developments,
preclinical development, clinical trials, recruitment of patients,
product development activities and regulatory approval
requirements; that preclinical or interim results and data from
ongoing clinical studies of the company’s cytokine programs and
product candidates may not be predictive of future or final results
from such studies, results of future clinical studies or real-world
results; future clinical trials or future stages of ongoing
clinical trials may not be initiated or completed on time or at
all; the company’s product candidates, including nemvaleukin, could
be shown to be unsafe or ineffective; changes in the cost, scope
and duration of development activities; the U.S. Food and Drug
Administration may make adverse decisions regarding the company’s
product candidates; and those other risks and uncertainties set
forth in the company’s filings with the Securities and Exchange
Commission (“SEC”), including its Quarterly Report on Form 10-Q for
the quarterly period ended June 30, 2024 and in subsequent filings
the company may make with the SEC. All forward-looking statements
contained in this press release speak only as of the date of this
press release. The company anticipates that subsequent events and
developments will cause its views to change. However, the company
undertakes no obligation to update such forward-looking statements
to reflect events that occur or circumstances that exist after the
date of this press release, except as required by law.
Contact:Katie
Sullivankatie.sullivan@muraloncology.com
Mural Oncology (NASDAQ:MURA)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Mural Oncology (NASDAQ:MURA)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024